Document is current
Any future updates will be listed below
-
Authors
Woronko, Sarah E. https://orcid.org/0000-0001-6517-4106
Li, Mohan
Scott, Jason N. Jr
Kuhn, Manuel
Esfand, Shiba M.
Bogdanov, Mario
Boyle, Brian W.
Linton, Samantha R.
Borchers, Lauren R.
Zhukovsky, Peter
Miller, Courtney
Bolton, Paula
Li, Shuang
Meisner, Robert C.
Lees, Ty https://orcid.org/0000-0002-7321-2704
Pizzagalli, Diego A. https://orcid.org/0000-0002-7772-1143
-
Funding
Funding for this research was provided by:
Millennium Therapeutics (Study 1) WellcomeLeap MCPsych
- License Information
-
More Information
Article History
Received: 3 February 2025
Accepted: 4 August 2025
First Online: 4 September 2025
Competing interests
: Over the past three years, D.A.P. has received consulting fees from Arrowhead Pharmaceuticals, Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, Neurocrine Biosciences, Neuroscience Software, Sage Therapeutics and Takeda; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and from Alkermes; he has received research funding from the BIRD Foundation, Brain and Behavior Research Foundation, Dana Foundation, DARPA, Millennium Pharmaceuticals, NIMH and Wellcome Leap MCPsych; he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics and Neuroscience Software. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. The other authors declare no competing interests.
